The battle over embryonic stem cell research is over. A few skirmishes will no doubt continue—perhaps even for years—and some ESCR advocates will refuse to acknowledge defeat. But they have decisively lost. Years from now, when we look back in astonishment at having been fleeced for billions to pay for therapeutically worthless research, we’ll recognize that California was the Waterloo for ESCR.